A level of 100?L cells was added into anti-IFN- coated ELISPOT dish and activated with 100?L complete RPMI containing: 20?g/mL R9F or unimportant peptide R9L, 100?L C3 cells or Panc02 cells, or zero peptide (background control)

A level of 100?L cells was added into anti-IFN- coated ELISPOT dish and activated with 100?L complete RPMI containing: 20?g/mL R9F or unimportant peptide R9L, 100?L C3 cells or Panc02 cells, or zero peptide (background control). Data evaluation and statistical

Within an absolute bioavailability microdose trial, the oral therapeutic dose designed for clinical use is administered, and the intravenous microdose is administered concomitantly on the approximated maximum plasma concentration from the oral dose (Body?1)

Within an absolute bioavailability microdose trial, the oral therapeutic dose designed for clinical use is administered, and the intravenous microdose is administered concomitantly on the approximated maximum plasma concentration from the oral dose (Body?1). medication. 1 For implemented medications orally,